Ethnic and geographic differences in cancer incidence, prognosis, and treatment outcomes
can be attributed to diversity in the inherited (germline) and somatic genome. Although …

Purpose: Non-small-cell lung cancers harboring EML4-ALK rearrangements are sensitive to
crizotinib. However, despite initial response, most patients will eventually relapse, and …

Dysregulation of the AXL receptor tyrosine kinase has been associated with many types of
cancer. It has not been until recently, however, that targeting AXL has come under the …

Non‐small cell lung cancer (NSCLC) is one of the most deadly cancers worldwide, with poor
prognosis once the disease has progressed past the point at which surgery is a viable …

T790M mutation is the most common mechanism for resistance to first-and second-
generation tyrosine kinase inhibitors (TKI) for epidermal growth factor receptor (EGFR) …

Centrosome-localized mitotic Aurora kinase A (AURKA) facilitates G2/M events. Here we
show that AURKA translocates to the nucleus and causes distinct oncogenic properties in …

Understanding the molecular landscape of cancer has facilitated the development of
diagnostic, prognostic, and predictive biomarkers for clinical oncology. Developments in …

Lung cancer diagnostics have progressed greatly in the previous decade. Development of
molecular testing to identify an increasing number of potentially clinically actionable genetic …

Anaplastic lymphoma kinase-rearranged lung cancer is associated with significant response
to crizotinib. However, resistance to crizotinib typically develops within 1-2 years. Preclinical …

Precision oncology is now the evidence-based standard of care for the management of
many advanced non-small cell lung cancers (NSCLCs). Expert consensus has defined …